98 related articles for article (PubMed ID: 24778392)
21. Trastuzumab emtansine. An inadequately assessed combination of two cytotoxic drugs.
Prescrire Int; 2014 Dec; 23(155):289. PubMed ID: 25629144
[TBL] [Abstract][Full Text] [Related]
22. Corneal Epitheliopathy Associated With Antibody-Drug Conjugates.
Patel SV; Dalvin LA
Mayo Clin Proc; 2021 Jul; 96(7):2001-2002. PubMed ID: 34218869
[No Abstract] [Full Text] [Related]
23. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
[TBL] [Abstract][Full Text] [Related]
24. The promise of antibody-drug conjugates.
Teicher BA; Doroshow JH
N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
[No Abstract] [Full Text] [Related]
25. Desensitization to chemotherapeutic agents.
Lieberman P; Castells M
J Allergy Clin Immunol Pract; 2014; 2(1):116-7. PubMed ID: 24565784
[No Abstract] [Full Text] [Related]
26. Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report.
Kwon Y; Gomberg-Maitland M; Pritzker M; Thenappan T
Chest; 2016 Apr; 149(4):e103-5. PubMed ID: 27055712
[TBL] [Abstract][Full Text] [Related]
27. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
Lambert JM; Chari RV
J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
[TBL] [Abstract][Full Text] [Related]
28. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
Beeram M; Krop IE; Burris HA; Girish SR; Yu W; Lu MW; Holden SN; Modi S
Cancer; 2012 Dec; 118(23):5733-40. PubMed ID: 22648179
[TBL] [Abstract][Full Text] [Related]
29. Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?
Sendur MA; Aksoy S; Ozdemir Y; Zengin N; Altundag K
J BUON; 2013; 18(3):801. PubMed ID: 24065505
[No Abstract] [Full Text] [Related]
30. T-DM1 aids patients with advanced breast cancer.
Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
[No Abstract] [Full Text] [Related]
31. A case of vasculitis in a breast cancer patient treated with T-DM1.
Bhardwaj AS; McLellan B; Robinson MR; Ghaw O; Lipsey LR; Tiersten AD; Morris GJ
Semin Oncol; 2014 Oct; 41(5):e39-45. PubMed ID: 25440614
[No Abstract] [Full Text] [Related]
32. Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages.
Benguerfi S; Diéras V; Campone M; Mosnier JF; Robert M
Acta Oncol; 2020 Mar; 59(3):306-309. PubMed ID: 31556755
[No Abstract] [Full Text] [Related]
33. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
Uppal H; Doudement E; Mahapatra K; Darbonne WC; Bumbaca D; Shen BQ; Du X; Saad O; Bowles K; Olsen S; Lewis Phillips GD; Hartley D; Sliwkowski MX; Girish S; Dambach D; Ramakrishnan V
Clin Cancer Res; 2015 Jan; 21(1):123-33. PubMed ID: 25370470
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
[TBL] [Abstract][Full Text] [Related]
36. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Bender BC; Schaedeli-Stark F; Koch R; Joshi A; Chu YW; Rugo H; Krop IE; Girish S; Friberg LE; Gupta M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):591-601. PubMed ID: 22886072
[TBL] [Abstract][Full Text] [Related]
37. Interest in "smart bombs" explodes.
Cancer Discov; 2012 Oct; 2(10):864. PubMed ID: 23071018
[No Abstract] [Full Text] [Related]
38. Nodular regenerative hyperplasia of the liver with and without portal hypertension: a comparison.
Harada A; Nakanuma Y; Govindarajan S; Peters RL
Ann Clin Lab Sci; 1986; 16(2):155-62. PubMed ID: 3963734
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
Mathew J; Perez EA
Curr Opin Oncol; 2011 Nov; 23(6):594-600. PubMed ID: 21986845
[TBL] [Abstract][Full Text] [Related]
40. Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer.
Romero D
Nat Rev Clin Oncol; 2024 Jun; 21(6):402. PubMed ID: 38528141
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
